Treatment Overview

Treatment considerations for the BEXXAR therapeutic regimen¹

Contraindicated in patients with known hypersensitivity to murine protein or any components of BEXXAR
Pregnancy Category X: The BEXXAR therapeutic regimen can cause fetal harm when administered to a pregnant woman and is contraindicated for use in women who are pregnant
Women who are breast-feeding should discontinue nursing
There is a potential toxic effect on the male and female reproductive systems. Patients should be instructed to use effective contraceptive methods during treatment and for 12 months following the administration of the BEXXAR therapeutic regimen
The BEXXAR therapeutic regimen should not be administered to patients with >25% lymphoma bone marrow involvement, platelet counts <100,000 platelets/mm³, or neutrophil counts <1,500 cells/mm³
The recommended total body radiation dose of BEXXAR is:
- 75 centiGray (cGy) for patients with platelet counts >150,000
platelets/mm³
- 65 cGy for patients with platelet counts of 100,000 to <150,000
platelets/mm³
Iodine I 131 Tositumomab and Iodine-131 are excreted primarily by the kidneys. Impaired renal function may decrease the rate of excretion of the radiolabeled iodine and increase patient exposure to the radioactive component of the BEXXAR therapeutic regimen

Complete Prescribing Information for
BEXXAR (Tositumomab and Iodine I 131 Tositumomab)